First-in-Human trial tests re-engineered immune cells to fight advanced cancers
NCT ID NCT06942143
Summary
This is an early-stage safety study testing a new personalized cell therapy for adults with advanced sarcoma, lung cancer, or melanoma. Doctors take a patient's own immune cells, modify them in a lab to better target a specific protein found on their cancer cells, and then infuse them back. The main goals are to find a safe dose and see what side effects occur.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Gaungdong, 510700, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.